机译:Bardoxolone甲基dh404的反剂量依赖性,可减轻糖尿病相关的动脉粥样硬化并改善糖尿病肾病
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Epigenomic Medicine, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Reata Pharmaceuticals, Inc., Irving, TX;
Reata Pharmaceuticals, Inc., Irving, TX;
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
Oxidative Stress Laboratory, Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
机译:Bardoxolone甲基提高了慢性肾病阶段4和2型糖尿病患者的肾功能:在慢性肾病患者和2型糖尿病研究中,HARDOXOLENE甲基评估后HOC分析
机译:Bardoxolone甲基的新型衍生物改善了治疗糖尿病肾病的安全性
机译:随机化临床试验对糖尿病肾病患者GFR对GFR的影响(Tsubaki研究)
机译:Bardoxolone甲基改善慢性肾脏病4期和2型糖尿病患者的肾功能:Bardoxolone甲基评估慢性肾脏病和2型糖尿病患者的Hoc分析
机译:Bardoxolone甲基,DH404的衍生物,依赖于剂量依赖性方式减少糖尿病相关动脉粥样硬化并改善糖尿病肾病